findmyKOL

Barbara Widom, MD

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDNone on fileNPI
RegionFort Collins, CO · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication1995Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Barbara Widom is an Endocrinology/Metabolic physician. OpenAlex indexes 8 publications with 509 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
8publications

Distinct works indexed by OpenAlex.

509citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1106 E Prospect Rd
Suite 100
Fort Collins, CO 805255306

Telephone

970-224-3636

Registry record last updated 26 Jan 2015.

View the NPPES registry record

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    77.1%
    Other drugs affecting bone structure and mineralization54.1%
    Romosozumab-aqqg100%
    Part B, office-administered12 patients
    RANK Ligand Inhibitor23%
    Denosumab100%
    Part B, office-administered40 patients
  • Metabolism & gastrointestinal

    9.5%
    GLP-1 receptor agonist2.9%
    Mounjaro79%Trulicity13%Ozempic8%
    Part D<11 patients
    Insulin Analog2.9%
    Tresiba Flextouch U-10017%Novolog Flexpen12%Humalog Kwikpen U-10011%Insulin Lispro Kwikpen U-1009%Tresiba Flextouch U-2008%Toujeo Solostar7%Lantus Solostar7%Insulin Lispro6%Novolog6%Fiasp Flextouch5%Humalog5%Toujeo Max Solostar5%Lantus3%
    Part D<11 patients

    + 7 more classes in this area

  • Hormonal (systemic)

    7.2%
    l-Thyroxine6.1%
    Levothyroxine Sodium84%Synthroid16%
    Part D206 patients
    Thyroid Hormone Synthesis Inhibitor0.6%
    Methimazole100%
    Part D30 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”